Healthcare & Devices
Cardiovascular Consumable · Angel US$6M
By laying out the NMPA registration path and FDA 510(k) timeline in parallel, the team avoided duplicate validation and compressed an 18-month regulatory path to 11 months.
Regulatory path cut
-39%
First clinical sites
8
Valuation multiple
5.7x
The team originally planned for NMPA only. The platform's policy scan found a 70% overlap between NMPA and FDA in device classification and clinical-dataset definitions.
The platform delivered a dual-track registration timeline + clinical-site priority (by enrollment speed × data compliance) and connected the team to 3 CROs experienced in dual-track filings.
Outcome: 65% data reuse between NMPA Class III and FDA 510(k), saving $1.2M of duplicate clinical budget.
Closed a $6M angel round at a $36M pre-money valuation.